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Abstract
Background: Acute lung injury (ALI) is a serious clinical syndrome with a high rate of mortality. In this study, the
effects of triptolide on lipopolysaccharide (LPS)-induced ALI in rats were investigated.
Methods: Sixty-five male Sprague Dawley rats(approved by ethics committee of the First Affiliated Hospital of
Soochow University) were randomly divided into five groups. The control group was injected with 2.5 mL saline/kg
body weight via the tail vein and intraperitoneally with 1% dimethyl sulfoxide (DMSO) (n = 5). The L group was
administered with 0.2% LPS dissolved in saline (5 mg/kg) to induce ALI via the tail vein (n = 15). The TP1, TP2, and
TP3 groups were treated as rats in the L group and then intraperitoneally injected with 25, 50, and 100 μg
triptolide/kg body weight, respectively (15 rats per group). Blood samples from the left heart artery were taken for
blood gas analysis at 1 hour before injection and at 1, 3, 6, and 12 hours after saline and DMSO administration in
the control group, LPS injection in the L group, and triptolide injection in the TP1, TP2, and TP3 groups. Lung
wet-to-dry weight (W/D) ratio, diffuse alveolar damage (DAD) score, TNF-α levels, and mRNA and protein expression
of toll-like receptor 4 (TLR4) were analyzed.
Results: Compared with the control group, the arterial partial pressure of oxygen (PaO2) declined (P <0.05), the
W/D ratio and DAD score increased (P <0.05), and TNF-α levels in serum and bronchoalveolar lavage fluid (BALF)
and mRNA and protein expression of TLR4 were significantly increased in the L group (P <0.05). Compared with the
L group, PaO2 significantly increased in the TP2 and TP3 groups (P <0.05), while the W/D ratio and DAD score were
significantly decreased in the TP2 and TP3 groups (P <0.05). TNF-α levels and mRNA and protein expression of TLR4
were significantly decreased in the TP2 and TP3 groups compared with the L group (P <0.05).
Conclusions: Triptolide can ameliorate LPS-induced ALI by reducing the release of the inflammatory mediator
TNF-α and inhibiting TLR4 expression.
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Background
Acute lung injury (ALI) or its more severe form, adult
acute respiratory distress syndrome (ARDS), is the pul-
monary manifestation of an acute systemic inflammatory
process and an important cause of mortality in the hu-
man population [1]. When ARDS occurs in the context
of multisystem organ failure, mortality can reach 60%
and can result in significant pulmonary impairment in
more than 50% of survivors [2-4]. Therefore, there is an
urgent need to improve treatment and prevention strat-
egies to minimize the mortality of ALI.
Triptolide, a diterpenetriepoxide, is extracted from
Tripterygium wilfordii, which is a traditional Chinese
medicine and has multiple pharmacological activities
including immunosuppressive, anti-inflammatory, and anti-
tumor activities [5-7]. Triptolide exhibits anti-inflammatory
activities in cultured lung cells and in rat models with acute
chlorine-induced lung injury [8]. However, there have been
no reports to date on triptolide activity for lipopolysacchar-
ide (LPS)-induced ALI.
LPS is a component of the cell wall in gram-negative
bacteria. In a clinical situation, ARDS is usually induced
by LPS shock, which is very difficult to treat and is asso-
ciated with high mortality [1]. ARDS is a major compli-
cation in patients with leukemia, AIDS, transplantation,
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and steroid treatment. LPS inducing in an animal model
has been developed as a means to establish an ALI
model and test potential therapies [9-11]. In lung injury,
arterial partial pressure of oxygen (PaO2), lung wet-to-
dry weight (W/D) ratio, and diffuse alveolar damage
(DAD) can be used as indicators of lung injury according
to previous reports [12,13]. LPS activates monocytes and
macrophages to produce cytokines such as TNF-α, IL-1,
and IL-6 that serve as endogenous inflammatory media-
tors [14,15]. TNF-α is one of the cytokines that can
induce pulmonary permeability and edema [16].
The sensing of LPS by innate immune cells is vital for
host defenses against gram-negative bacteria. Toll-like re-
ceptor 4 (TLR4) can recognize LPS and activate innate im-
munity, meanwhile transmit signals to antigen-presenting
cells and activate acquired immunity [17]. Wu et al. [18]
found that TLR4 played a critical role in LPS-induced ALI
and transfection of adenovirus Ad-siTLR4 could effect-
ively downregulate TLR4 expression in vitro and in vivo,
accompanied by alleviation of LPS-induced lung injury. A
recent study demonstrated that plasminogen activator in-
hibitor type-1 (PAI-1) increased the expression of TLR4 to
promote lung injury [19]. Thus a therapeutic strategy
against these abnormalities and targets could be effective
for ARDS treatment.
This study aimed to investigate whether triptolide can
ameliorate LPS-induced ALI and to explore the possible
mechanisms responsible for the effects of triptolide on
LPS-induced ALI. PaO2, lung W/D ratios, and DAD
scores were determined to assess whether the ALI rat
model is well established and the function of triptolide.
TNF-α levels in serum and bronchoalveolar lavage fluid
(BALF) and mRNA and protein expression of TLR4
were analyzed to explore the possible mechanisms.
Methods
Animal models
All protocols were performed in accordance with guide-
lines of the Ethics Committee of the First Affiliated Hos-
pital of Soochow University, Jiangsu, China. Sixty-five male
Sprague Dawley rats weighing 200 to 250 g (purchased
from Shanghai Slack Laboratory Animal Limited Liability
Company, Shanghai, China) were used in the study. The
animals were randomly divided into five groups: control
group (n = 5), L group (n = 15), TP1 group (n = 15), TP2
group (n = 15), and TP3 group (n = 15). The control group
was injected via the tail vein with saline (2.5 mL/kg body
weight) and intraperitoneally with 1% dimethyl sulfoxide
(DMSO) (Sigma-Aldrich, St Louis, MO, USA). The L
group was administered via the tail vein with 0.2% LPS
(Escherichia coli serotype O111: B4, Sigma-Aldrich) and
dissolved in saline (5 mg/kg) to induce ALI. The TP1,
TP2, and TP3 groups were treated as rats in the L group
and then intraperitoneally injected with 25, 50, and
100 μg triptolide (dissolved in 1% DMSO, a gift from
Nanjing Institute of Skin Disease Prevention and Con-
trol, Nanjing, China)/kg body weight, respectively.
Collection of blood and bronchoalveolar and
measurement of TNF-α in serum and BALF
Rats were anesthetized with chloral hydrate (300 mg/kg)
and then blood (0.3 mL) was collected from the left heart
artery for blood gas analysis by an artery blood gas
analyzer (Nova Biomedical, Waltham, MA, USA) at 1 hour
before injection and at 1, 3, 6, and 12 hours after saline
and DMSO administration in the control group, LPS in-
jection in the L group, and triptolide injection in the TP1,
TP2, and TP3 groups. Blood was anticoagulated by
heparin and centrifuged at 2,000 rpm for 20 minutes at
4°C. Supernatant was then collected and stored at −20°C.
After blood collection at 12 hours, as mentioned above,
rats were killed with an overdose of pentobarbital. The right
bronchus was clamped and a 24G trocar (BD, Franklin
Lakes, USA) was placed in the cannula through the tracheal
ring gap. The bronchoalveolar was washed with 25 mL/kg
saline three times at 4°C. BALF obtained from rats was
pooled and centrifuged at 1,200 rpm for 10 minutes at 4°C.
The supernatant was then taken and stored at −20°C. TNF-
α levels in the serum and BALF were determined by an
enzyme-linked immunosorbent assay (ELISA) kit (R&D
Systems, Minneapolis, MN, USA).
Collection of lung tissue and measurement of lung W/D
After rats were executed, the inferior lobe of the right
lung was taken and washed with saline at 4°C. The tissue
was plated in ice and cut into pieces. Next, 100 mg of
tissue was placed in centrifuge tubes containing RNAla-
ter and incubated at room temperature for 1 hour, then
4°C overnight, and stored at −20°C until RNA extraction
and PCR. The remaining inferior lobe of the right lung
was cut into small pieces and placed in freezing tubes
equipped with glycerol. It was then frozen with liquid
nitrogen for 10 minutes and stored at −70°C until histo-
logical examination and western blot analysis.
The lung W/D ratio was calculated as previously
described [20]. The middle lobe of the right lung was
excised and rinsed with saline at 4°C, blotted with filter
paper to absorb the surface water, and weighed to obtain
the wet weight (W). The lung was then placed in an
oven at 80°C for 24 hours to obtain the dry weight (D).
Finally, the lung W/D ratio was calculated.
Histological examination
Lung tissues were fixed in 4% paraformaldehyde (PFA),
embedded in paraffin, and cut into 5 μm thick sections.
Tissues were stained with hematoxylin and eosin (H&E)
and observed with a Nikon Eclipse E800 microscope
(Nikon, Tokyo, Japan). ALI was scored (as described
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previously) [21] according to the following DAD cri-
teria: 1) effusion of neutrophils to the alveolar space
and the interval: 0 (no effusion), 1 (doubtful effusion), 2
(scattered effusion), and 3 (more or special mess distrib-
uted’ effusion)); 2) broadening of the alveolar septum: 0
(no broadening), 1 (a little broadening), 2 (clear broad-
ening), 3 (loss of the normal alveolar structure); 3)
bleeding in the alveolar space: 0 (no red blood cells), 1
(a few red blood cells), 2 (more red blood cells), and 3
(almost filled with red blood cells); and 4) effusion of
the fibrin in the alveolar space: 0 (no fibrin), 1 (a few
fibrin), 2 (more fibrin), and 3 (almost filled with fibrin).
Scores were added up and expressed as mean ± SD
(standard deviation).
Extraction of RNA and quantitative PCR analysis
Total RNA was extracted from the lung tissue using TRI-
zol Reagent (Invitrogen, Carlsbad, CA, USA). RNA purifi-
cation was conducted with an RNeasy kit (Takara, Shiga,
Japan) and residual DNA was removed by DNase I
(Takara). PCR primers were designed using Primer Premier
version 5.0 software (Premier Biosoft, Palo Alto, CA, USA)
and sequences were as follows (Invitrogen): TLR4: forward:
5′- CCTTTCCTGCCTGAGACC-3′, reverse: 5′-TTCTT
GGTTGAATAAGGGATGT-3′, product length: 123 bp;
β-actin: forward: 5′-CCCATCTATGAGGGTTACGC-3′,
reverse: 5′-TTTAATGTCACGCACGATTTC-3′, product
length: 150 bp. β-actin was used as an internal standard.
Quantitative PCR reaction conditions were as follows:
initial denaturation at 95°C for 2 minutes followed by
40 cycles of denaturation at 95°C for 10 seconds, an-
nealing at 60°C for 15 seconds, and extension at 72°C
for 20 seconds. The comparative CT method (also
known as the 2-ΔΔCT method) was used to calculate the
relative expression of TLR4 [22].
Western blot analysis
The inferior lobe of the right lung was stored with gly-
cerol at −70°C and taken for western blot analysis. The
total protein of the lung tissue was extracted and the
concentration was determined using a BCA Protein
Quantification Kit (Abcam, Honggkong, China). Next,
50 μg of protein was loaded, separated by 10% SDS-
PAGE, and transferred to polyvinylidene difluoride
(PVDF) membranes. After blocking with 5% nonfat dry
milk at room temperature for 1 hour and 4°C overnight,
the membranes were blotted with the primary anti-
bodies, including TLR4 and GAPDH antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), for 2 hours
at 37°C. Membranes were washed with Tris-buffered sa-
line containing 0.2 to 0.4% Tween-20 (TBST) three
times and then incubated with horseradish peroxidase
(HRP) conjugated rabbit-anti-mouse secondary anti-
bodies (Shanghai Boyao Biotechnology, Shanghai, China)
for 1 hour at room temperature. The optical density was
detected by a gel image analysis system (Bio Image
System,Inc, Aquarias, Singapore.
Statistical analysis
Data were analyzed using the SAS statistical package
(version 8; SAS Institute, Cary, NC, USA) and presented
as means ± standard deviation. One-way analysis of vari-
ance (ANOVA) was used for comparison among groups.
Data was considered statistically significant when P <0.05.
Results
Effect of triptolide on LPS-induced lung PaO2
Table 1 demonstrates that PaO2 in the L group declined
by 44.04% after injection of LPS compared with before
injection. PaO2 in the L group decreased significantly
after approximately 3 to 12 hours of LPS injection
Table 1 Effect of triptolide on partial pressure of oxygen
(PaO2), partial pressure of carbon dioxide (PaCO2), and









group (n = 5)
1 104.4 ± 2.3 35.6 ± 2.2 7.3 ± 0.1
1 101.4 ± 2.7 36.4 ± 2.3 7.4 ± 0.0
3 103.9 ± 3.0 35.5 ± 2.2 7.4 ± 0.0
6 102.1 ± 3.8 34.6 ± 3.2 7.3 ± 0.1
12 103.8 ± 3.0 35.9 ± 3.7 7.4 ± 0.1
L group
(n = 15)
1 102.1 ± 2.4 35.5 ± 3.1 7.3 ± 0.0
1 94.7 ± 6.7 36.2 ± 4.4 7.3 ± 0.1
3 72.5 ± 8.2a 35.5 ± 4.7 7.2 ± 0.2
6 64.2 ± 6.8a 36.6 ± 5.8 7.3 ± 0.2
12 57.2 ± 5.5a 36.9 ± 4.2 7.2 ± 0.3
TP1 group
(n = 15)
1 103.1 ± 2.4 35.6 ± 1.4 7.4 ± 0.1
1 93.5 ± 6.7 35.5 ± 1.9 7.3 ± 0.1
3 72.5 ± 7.6a 36.3 ± 2.4 7.3 ± 0.1
6 59.2 ± 6.8a 36.9 ± 4.7 7.3 ± 0.2
12 53.4 ± 8.2a 36.5 ± 5.0 7.3 ± 0.2
TP2 group
(n = 15)
1 105.1 ± 2.4 35.5 ± 1.6 7.3 ± 0.0
1 94.8 ± 6.4 35.3 ± 1.6 7.4 ± 0.1
3 79.9 ± 7.2a 35.8 ± 2.2 7.3 ± 0.1
6 82.2 ± 6.8ab 36.2 ± 3.8 7.3 ± 0.2
12 77.4 ± 7.4ab 36.4 ± 4.2 7.3 ± 0.2
TP3 group
(n = 15)
1 102.1 ± 2.4 35.4 ± 1.7 7.4 ± 0.0
1 93.8 ± 5.7 35.3 ± 1.4 7.3 ± 0.1
3 83.8 ± 6.8a 35.9 ± 2.5 7.3 ± 0.2
6 79.2 ± 6.8ab 35.6 ± 3.4 7.3 ± 0.2
12 74.4 ± 5.6ab 36.0 ± 3.6 7.3 ± 0.2
Data presented as mean ± standard deviation. aP <0.05, compared with control
group; bP <0.05, compared with L group.
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compared with the control group (P <0.05). PaO2 in the
TP2 and TP3 groups were relatively higher at 6 and
12 hours compared with the L group (P <0.05). PaCO2
and pH values had no statistical significance among
these groups (P >0.05).
Effect of triptolide on LPS-induced lung pathological
changes
H&E staining results showed that the alveolar structure of
the control group was complete and had no abnormal
changes such as effusion of inflammatory cells and broad-
ening of the pulmonary interstitial space (Figure 1a). After
injection of LPS, there was significant alveolar interval
widening, white blood cell exudation and gathering, pul-
monary capillary expansion and congestion, alveolar cavity
effusion, and even transparent membrane formation could
be observed (Figure 1b). Pathological changes such as
alveolar septum and effusion of inflammatory cells could
be seen in groups TP1, TP2, and TP3 under microscope.
But pathological changes of groups TP2 and TP3 were
lighter than group TP1 (Figure 1c,d,e).
Effect of triptolide on DAD score and W/D ratio
Pulmonary edema is a hallmark of ALI, and the standard
assessment of edema is to measure the amount of water
in the lungs. Table 2 shows the DAD score and W/D ra-
tio for the control group, L group, and TP1, TP2, and
TP3 groups. The DAD score and W/D ratio in the L
group was 3.8 and 1.7 times greater than the control
group, respectively (P <0.05). In the TP1 group, the
DAD score and W/D ratio were not significantly differ-
ent compared with those of the L group, and lower in
the TP2 and TP3 groups than in the L group (P <0.05).
Effect of triptolide on TNF-α levels in serum and BALF
As shown in Figure 2, TNF-α in serum and BALF were
increased by 1.8 and 1.7 times, respectively, in the L
group compared with the control group (P <0.05) and
also higher in the TP1 group compared with the control
group (P <0.05). However, there was no statistical signifi-
cance between the TP1 group and L group (P >0.05).
TNF-α in serum and BALF were significantly decreased
in the TP2 and TP3 groups compared with the L group
(P <0.05). It was observed that TNF-α levels decreased
with the increase of triptolide dose. The results showed
Figure 1 Lung pathologies. (a) Control group, (b) L group, (c) TP1 group, (d) TP2 group, and (e) TP3 group with hematoxylin-eosin (H&E) staining
(×400). Injection of LPS caused infiltration of inflammatory cells into the lung interstitial and alveolar spaces, alveolar wall thickening, and intra-alveolar
exudation. In TP1, TP2, and TP3 groups, triptolide attenuated these histological changes. LPS, lipopolysaccharide.
Table 2 Effect of triptolide on the diffuse alveolar
damage (DAD) score and wet-to-dry weight ratio (W/D)
Group DAD score W/D ratio
Control group (n = 5) 2.55 ± 0.45 3.49 ± 0.18
L group (n = 15) 9.84 ± 1.50a 5.84 ± 0.32a
TP1 group (n = 15) 9.22 ± 1.35a 5.39 ± 0.24a
TP2 group (n = 15) 6.35 ± 1.05ab 4.42 ± 0.26ab
TP3 group (n = 15) 5.40 ± 0.65ab 4.23 ± 0.22ab
Data are presented as mean ± standard deviation. aP <0.05, compared with
control group; bP <0.05, compared with L group.
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that triptolide inhibited TNF-α expression in a dose-
dependent manner (P <0.05).
Effect of triptolide on expression level of TLR4
As shown in Figure 3, mRNA and protein expression
levels of TLR4 were upregulated in the L group com-
pared with the control group (P <0.05). However, there
was no statistical significance between the TP1 group
and L group (P >0.05). Their levels were significantly
downregulated in the TP2 and TP3 groups compared
with the L group (P <0.05). The mRNA and protein
expression levels decreased with the increase of tripto-
lide dose. Triptolide affected expression levels of TLR4
in a dose-dependent manner (P <0.05).
Discussion
ALI can be induced by exposure of the lung to LPS [23]
and in this study we used LPS-induced rats to assess the
function of triptolide. The results showed that triptolide
can increase the PaO2 level, ameliorate LPS-induced
histological changes, and attenuate the increased DAD
value and lung W/D ratio after LPS injection. Triptolide
also decreased the levels of TNF-α in serum and BALF
and reduced mRNA and protein expression levels of
TRL4.
In the present study, a rat model of ALI was estab-
lished by tail vein injection of LPS, which decreased
PaO2 and increased DAD values and lung W/D ratios.
Rojas et al. [12] observed that endotoxin (LPS) injection
led to an increase of W/D ratio and changes of histology
which could be characterized as the onset of ALI. DAD
is a well-recognized histological pattern associated with
an acute clinical presentation [24]. Our results indicated
that triptolide intervention can improve PaO2, decrease
W/D ratio and pulmonary edema, and alleviate lung
injury in ALI rats. Laffey et al. [25] observed that
hypercapnic acidosis attenuated the increased PaO2 in
LPS-induced ALI. Itoh et al. [26] demonstrated that
adrenomedullin attenuated the increase of lung W/D
ratio and histological changes to ameliorate ALI [26].
Taken together, the studies indicate that triptolide ame-
liorates LPS-induced ALI in rats.
LPS has been reported to induce production of several
cytokines. TNF-α is a proinflammatory cytokine and
participates in several important processes involved in
inflammatory response. Triptolide is the most potent
inhibitor of lung inflammation in a library of 446
Figure 2 Effect of triptolide on TNF-α levels. (a) Serum and (b) BALF. Data presented as mean ± standard deviation. *P <0.05, compared with
control group; △P <0.05, compared with L group. Pairwise comparison among TP1, TP2, and TP3 groups: #P <0.05, compared with TP1 group; §P <0.05,
compared with TP2 group. BALF, bronchoalveolar lavage fluid.
Figure 3 Effect of triptolide on expression level of TLR4. (a) mRNA and (b) protein expression of TLR4 in rat lung tissue.*P <0.05, compared
with control group; △P <0.05, compared with L group. Pairwise comparison among TP1, TP2, and TP3 groups: #P <0.05, compared with TP1 group;
§P <0.05, compared with TP2 group.
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compounds in the National Institutes of Health (NIH)
Clinical Collection [8]. In our study, TNF-α markedly
increased in serum and BALF after LPS injection and trip-
tolide decreased the TNF-α level. The results can be sup-
ported by earlier in vitro findings that the triptolide
suppresses the TNF-α/TNFR2 signal pathway in IL-10-
deficient mice [27]. This study showed that triptolide
reduced LPS-stimulated lung inflammation through inhib-
ition of TNF-α production.
TLR4 plays a critical role in LPS-induced ALI [18].
Baumgarten et al. [28] found that the pulmonary gene
expression of proinflammatory cytokines such as TNF,
IL-1β, and IL-6 as well as their corresponding receptors
TNFRp75 and IL-1RII were regulated by LPS via TLR4. In
our study, mRNA and protein expression levels of TLR4
increased after injection of LPS in rats and triptolide infu-
sion attenuated the increase, which corresponded with
TNF-α level changes in serum and BALF. A previous
study showed that triptolide suppressed TLR expression
in IL-1β-treated human intervertebral disc cells [29]. Trip-
tolide ameliorated Crohn’s colitis associated with inhib-
ition of the TLR/NF-κB signaling pathway [30]. The
results demonstrated that triptolide canameliorate LPS-
induced ALI via TLR4. However, details of the regulation
of TLR4 in LPS-induced ALI by triptolide requires further
study.
Conclusions
In summary, triptolide can ameliorate LPS-induced ALI
by reducing the release of the inflammatory mediator
TNF-α and inhibiting TLR4 expression. These results
demonstrate that triptolide could provide potential therapy
for LPS-induced ALI.
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